Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
Thiazides to prevent rolling stones - the Ten Tweet summary of NOSTONE is here.
Welcome to #TenTweetNephJC - we’re again covering a practice changing trial, but unfortunately one that shows a treatment we’ve prescribed for decades for kidney stone prevention ain’t doing a huge amount....🧵 pic.twitter.com/j23gn9grw1
— Nephrology Journal Club (@NephJC) May 3, 2023
Check out the crisp VA on NOSTONE trial by Renz Pasilan
What’s your loop and thiazide of choice? Do you know which diuretics are better, faster, stronger? This week’s TenTweets is a two-fer (Chlorthalidone vs HCTZ and Furosemide vs Torsemide). Tweetorial catch-up here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) February 10, 2023
✳️10 tweets #NephJC catch-up ✳️
We all have our “go to” diuretics that are better, faster, stronger…but are they?
What evidence is there that one diuretic (in a class) is superior to another for CV outcomes?
It’s a 2-fer TenTweets.
Let’s go… pic.twitter.com/9Ms3zg8Z5z